Toggle menu

PitSTOP

Start date:
August 2017
End date:
August 2018
Co-ordinated by:
Dr John Emelifeonwu and the EMERGE Team, RIE
Main trial site:
RIE

Primary Objective
To determine the prevalence of anterior pituitary gland dysfunction in traumatic brain injury in Scotland.

Secondary Objectives
To determine whether clinical and radiologically parameters available on presentation can predict likelihood of developing PTPD in patients with TBI.
To determine the optimal timing after TBI for blood tests to diagnose PTPD
To determine whether PTPD effects functional recovery as determined by the extended Glasgow Outcome Score (eGOS)

Chief Investigator

Dr John Emelifeonwu

Surgical Trainee, Clinical Neurosciences

Research Team

Mia Paderanga

Senior Research Nurse

Julia Grahamslaw

Lead Research Nurse

More EMERGE Trials

DASH Trial

DASH is a randomised clinical trial investigating a treatment to reverse the effects of blood-thinning medications.

Prospective multicentre observational study conducted over one calendar month in 2019, with the aim of describing the epidemiology of non-trauma related headache in adults presenting to emergency departments including investigations, treatments and outcome.

This will include adult patients presenting to the ED with non-trauma-related headache as their primary complaint.

Read more

HEAD Study

Developing a molecular tool to stratify the acute joint presentation: facilitating early diagnosis of septic arthritis (Septic Arthritis Biomarker Emergency Rule-out - SABER)

Read more

SABER Study

Developing a molecular tool to stratify the acute joint presentation: facilitating early diagnosis of septic arthritis (Septic Arthritis Biomarker Emergency Rule-out - SABER)